While Sage Therapeutics Inc has underperformed by -0.27%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SAGE fell by -72.19%, with highs and lows ranging from $27.39 to $4.62, whereas the simple moving average fell by -16.46% in the last 200 days.
On November 21, 2024, RBC Capital Mkts Upgraded Sage Therapeutics Inc (NASDAQ: SAGE) to Sector Perform. RBC Capital Mkts also Downgraded SAGE shares as ‘Sector Perform’, setting a target price of $4 on the company’s shares in a report dated October 04, 2024. TD Cowen July 30, 2024d the rating to Hold on July 30, 2024, and set its price target from $16 to $10. JP Morgan July 25, 2024d its ‘Overweight’ rating to ‘Neutral’ for SAGE, as published in its report on July 25, 2024. Robert W. Baird’s report from May 29, 2024 suggests a price prediction of $15 for SAGE shares, giving the stock a ‘Neutral’ rating. Citigroup also rated the stock as ‘Sell’.
Analysis of Sage Therapeutics Inc (SAGE)
Further, the quarter-over-quarter increase in sales is 337.08%, showing a positive trend in the upcoming months.
In order to gain a clear picture of Sage Therapeutics Inc’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of -49.34% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 10.02, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 1.66M can be a very valuable indicator of volatility for SAGE stock. On a monthly basis, the volatility of the stock is set at 5.62%, whereas on a weekly basis, it is put at 3.43%, with a gain of 4.56% over the past seven days. Furthermore, long-term investors anticipate a median target price of $8.60, showing growth from the present price of $7.33, which can serve as yet another indication of whether SAGE is worth investing in or should be passed over.
How Do You Analyze Sage Therapeutics Inc Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 12.02%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 79.84% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
SAGE shares are owned by institutional investors to the tune of 79.84% at present.
